{"article_title": "Novo Nordisk Targets Mexico for Anti-Obesity Drug", "article_keywords": ["novo", "nordisk", "antiobesity", "mexico", "targeted", "vice", "drug", "regulatory", "treatment", "tackle", "president", "senior", "root", "targets"], "article_url": "http://www.wsj.com/articles/SB10001424052702304899704579391182558656184", "article_text": "MEXICO CITY\u2014Danish insulin maker Novo Nordisk A/S plans to file for regulatory approval for its new anti-obesity drug in Mexico, in a bid to tackle one of the root causes of diabetes in a key market.\n\nThe company has targeted Mexico for an early launch of the treatment because of the country's high percentage of overweight people, said Mike Doustdar, senior vice president for international operations at Novo Nordisk.\n\nSeven out...", "article_metadata": {"article.template": "snippet", "article.created": "2014-02-18T19:25:00.000Z", "article.section": "Business", "page.region": "na,us", "page.content.type": "Article", "twitter": {"domain": "wsj.com", "description": "Danish insulin maker Novo Nordisk plans to file for regulatory approval for its new anti-obesity drug in Mexico, in a bid to tackle one of the root causes of diabetes in a key market.", "title": "Novo Nordisk Targets Mexico for Anti-Obesity Drug", "image": {"alt": "Novo Nordisk targets Mexico for anti-obesity drug", "identifier": "http://si.wsj.net/img/WSJ_Logo_black_social.gif"}, "site": "@WSJ", "card": "summary"}, "al": {"ios": {"url": "wsj://launch?articleid=SB10001424052702304899704579391182558656184&headline=Novo%20Nordisk%20targets%20Mexico%20for%20anti-obesity%20drug&weburl=http://www.wsj.com/articles/SB10001424052702304899704579391182558656184"}}, "page.site.product": "WSJ", "keywords": "anti-obesity drug,liraglutide,mexico,novo nordisk,obesity,overweight,victoza,Novo Nordisk,NVO,Mike Doustdar,political,general news,diabetes,health,medical conditions,pharmaceuticals,health care,life sciences", "news_keywords": "anti-obesity drug,liraglutide,mexico,novo nordisk,obesity,overweight,victoza,Novo Nordisk,NVO,Mike Doustdar", "article.headline": "Novo Nordisk targets Mexico for anti-obesity drug", "description": "Danish insulin maker Novo Nordisk plans to file for regulatory approval for its new anti-obesity drug in Mexico, in a bid to tackle one of the root causes of diabetes in a key market.", "apple-itunes-app": "app-id=364387007,app-argument=wsj://launch?articleid=SB10001424052702304899704579391182558656184&headline=Novo%20Nordisk%20targets%20Mexico%20for%20anti-obesity%20drug&weburl=http://www.wsj.com/articles/SB10001424052702304899704579391182558656184", "user.type": "nonsubscriber", "testkeys": "C", "article.page": "Business", "article.summary": "Danish insulin maker Novo Nordisk plans to file for regulatory approval for its new anti-obesity drug in Mexico, in a bid to tackle one of the root causes of diabetes in a key market.", "page.site": "wsj", "page.content.format": "responsive", "article.published": "2014-02-18T19:25:00.000Z", "dj.asn": "i-43d2", "robots": "noarchive,noodp", "fb": {"app_id": 368513495882}, "article": {"internal_link_count": 1, "word_count": 301, "publisher": "https://www.facebook.com/wsj"}, "viewport": "width=device-width, initial-scale=1.0, minimum-scale=1.0, maximum-scale=1.0, user-scalable=no", "page.section": "Article", "language": "en-US", "og": {"site_name": "WSJ", "description": "Danish insulin maker Novo Nordisk plans to file for regulatory approval for its new anti-obesity drug in Mexico, in a bid to tackle one of the root causes of diabetes in a key market.", "title": "Novo Nordisk Targets Mexico for Anti-Obesity Drug", "url": "http://www.wsj.com/articles/SB10001424052702304899704579391182558656184", "image": {"width": 1200, "identifier": "http://si.wsj.net/img/WSJ_Logo_black_social.gif", "height": 630}, "locale": "en_US", "type": "article"}, "author": "Amy Guthrie", "article.access": "paid", "page.content.source": "WSJ Online Article", "article.origheadline": "Novo Nordisk Targets Mexico for Anti-Obesity Drug", "article.type": "Business", "article.id": "SB10001424052702304899704579391182558656184", "user.exp": "default", "article.updated": "2014-02-18T19:25:00.000Z"}, "_id": "\"57477afa6914bd0286fe5a5b\"", "article_summary": "MEXICO CITY\u2014Danish insulin maker Novo Nordisk A/S plans to file for regulatory approval for its new anti-obesity drug in Mexico, in a bid to tackle one of the root causes of diabetes in a key market.\nThe company has targeted Mexico for an early launch of the treatment because of the country's high percentage of overweight people, said Mike Doustdar, senior vice president for international operations at Novo Nordisk.\nSeven out..."}